Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer

INTRODUCTIONThe initial treatment of differentiated thyroid cancer is thyroidectomy, followed by remnant ablation with iodine-131 (I-131) in some patients. However, controversy exists concerning the appropriate radioiodine dose. The aim of the study is to compare the success rate of low and high act...

Full description

Saved in:
Bibliographic Details
Published in:Nuclear medicine communications Vol. 33; no. 3; pp. 268 - 274
Main Authors: Caglar, Meltem, Bozkurt, Fani M, Akca, Ceren Kapulu, Vargol, Sezen Elhan, Bayraktar, Miyase, Ugur, Omer, Karaağaoğlu, Ergun
Format: Journal Article
Language:English
Published: England Lippincott Williams & Wilkins, Inc 01-03-2012
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract INTRODUCTIONThe initial treatment of differentiated thyroid cancer is thyroidectomy, followed by remnant ablation with iodine-131 (I-131) in some patients. However, controversy exists concerning the appropriate radioiodine dose. The aim of the study is to compare the success rate of low and high activities of I-131 for postoperative remnant ablation. PATIENTS AND METHODSA total of 108 nonmetastatic low-risk patients (mean age46, 85% women) with papillary and follicular carcinoma had I-131 ablation for the postoperative thyroid remnant. Fifty-three patients received a low dose (L) (800 MBq) and 55 patients received a high dose (H) (3700 MBq) of I-131. After total thyroidectomy, thyroid bed I-131 uptake (RAIU) and neck ultrasonography (USG) were performed to determine the remnant volume and the iodine avidity, which were used to calculate the dose delivered to the remnant tissue. The success rate of I-131 ablation was assessed with four different criteria based on serum thyroglobulin (Tg) and USG with and without the utilization of I-131 diagnostic whole-body scintigraphy (DxWBS). Ablation was considered to be successful if patients fulfilled all of the following criteria. (a) Strict criteria based on three tests(i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or up to 0.2% RAIU, and (iii) Tg<0.2 ng/ml; (b) lax criteria based on three tests(i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or ≤0.2% RAIU, and (iii) Tg<2 ng/ml; (c) strict criteria based on two tests(i) USG negative and (ii) Tg <0.2 ng/ml; (d) lax criteria based on two test(i) USG negative and (ii) Tg <2 ng/ml. RESULTSWhen three tests were used to define successful ablation, in group L, 32 out of 53 (60%) and 43 out of 53 (81%) patients were successfully treated versus 35 out of 55 (64%) and 42 out of 55 (76%) for group H on the basis of strict and lax criteria, respectively (P=NS). The differences were not statistically significant between the two groups when only two tests were used to define ablation success (62 vs. 69% with strict and 89 vs. 87% with lax criteria, respectively). CONCLUSIONOur findings suggest that remnant thyroid tissue in patients with low-risk, well-differentiated thyroid cancer after total thyroidectomy can be ablated with 800 MBq of I-131. The success rate is not different from that obtained with 3700 MBq I-131.
AbstractList The initial treatment of differentiated thyroid cancer is thyroidectomy, followed by remnant ablation with iodine-131 (I-131) in some patients. However, controversy exists concerning the appropriate radioiodine dose. The aim of the study is to compare the success rate of low and high activities of I-131 for postoperative remnant ablation. A total of 108 nonmetastatic low-risk patients (mean age: 46, 85% women) with papillary and follicular carcinoma had I-131 ablation for the postoperative thyroid remnant. Fifty-three patients received a low dose (L) (800 MBq) and 55 patients received a high dose (H) (3700 MBq) of I-131. After total thyroidectomy, thyroid bed I-131 uptake (RAIU) and neck ultrasonography (USG) were performed to determine the remnant volume and the iodine avidity, which were used to calculate the dose delivered to the remnant tissue. The success rate of I-131 ablation was assessed with four different criteria based on serum thyroglobulin (Tg) and USG with and without the utilization of I-131 diagnostic whole-body scintigraphy (DxWBS). Ablation was considered to be successful if patients fulfilled all of the following criteria. (a) Strict criteria based on three tests: (i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or up to 0.2% RAIU, and (iii) Tg < 0.2 ng/ml; (b) lax criteria based on three tests: (i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or ≤ 0.2% RAIU, and (iii) Tg < 2 ng/ml; (c) strict criteria based on two tests: (i) USG negative and (ii) Tg < 0.2 ng/ml; (d) lax criteria based on two test: (i) USG negative and (ii) Tg < 2 ng/ml. When three tests were used to define successful ablation, in group L, 32 out of 53 (60%) and 43 out of 53 (81%) patients were successfully treated versus 35 out of 55 (64%) and 42 out of 55 (76%) for group H on the basis of strict and lax criteria, respectively (P=NS). The differences were not statistically significant between the two groups when only two tests were used to define ablation success (62 vs. 69% with strict and 89 vs. 87% with lax criteria, respectively). Our findings suggest that remnant thyroid tissue in patients with low-risk, well-differentiated thyroid cancer after total thyroidectomy can be ablated with 800 MBq of I-131. The success rate is not different from that obtained with 3700 MBq I-131.
INTRODUCTIONThe initial treatment of differentiated thyroid cancer is thyroidectomy, followed by remnant ablation with iodine-131 (I-131) in some patients. However, controversy exists concerning the appropriate radioiodine dose. The aim of the study is to compare the success rate of low and high activities of I-131 for postoperative remnant ablation.PATIENTS AND METHODSA total of 108 nonmetastatic low-risk patients (mean age: 46, 85% women) with papillary and follicular carcinoma had I-131 ablation for the postoperative thyroid remnant. Fifty-three patients received a low dose (L) (800 MBq) and 55 patients received a high dose (H) (3700 MBq) of I-131. After total thyroidectomy, thyroid bed I-131 uptake (RAIU) and neck ultrasonography (USG) were performed to determine the remnant volume and the iodine avidity, which were used to calculate the dose delivered to the remnant tissue. The success rate of I-131 ablation was assessed with four different criteria based on serum thyroglobulin (Tg) and USG with and without the utilization of I-131 diagnostic whole-body scintigraphy (DxWBS). Ablation was considered to be successful if patients fulfilled all of the following criteria. (a) Strict criteria based on three tests: (i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or up to 0.2% RAIU, and (iii) Tg < 0.2 ng/ml; (b) lax criteria based on three tests: (i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or ≤ 0.2% RAIU, and (iii) Tg < 2 ng/ml; (c) strict criteria based on two tests: (i) USG negative and (ii) Tg < 0.2 ng/ml; (d) lax criteria based on two test: (i) USG negative and (ii) Tg < 2 ng/ml.RESULTSWhen three tests were used to define successful ablation, in group L, 32 out of 53 (60%) and 43 out of 53 (81%) patients were successfully treated versus 35 out of 55 (64%) and 42 out of 55 (76%) for group H on the basis of strict and lax criteria, respectively (P=NS). The differences were not statistically significant between the two groups when only two tests were used to define ablation success (62 vs. 69% with strict and 89 vs. 87% with lax criteria, respectively).CONCLUSIONOur findings suggest that remnant thyroid tissue in patients with low-risk, well-differentiated thyroid cancer after total thyroidectomy can be ablated with 800 MBq of I-131. The success rate is not different from that obtained with 3700 MBq I-131.
INTRODUCTIONThe initial treatment of differentiated thyroid cancer is thyroidectomy, followed by remnant ablation with iodine-131 (I-131) in some patients. However, controversy exists concerning the appropriate radioiodine dose. The aim of the study is to compare the success rate of low and high activities of I-131 for postoperative remnant ablation. PATIENTS AND METHODSA total of 108 nonmetastatic low-risk patients (mean age46, 85% women) with papillary and follicular carcinoma had I-131 ablation for the postoperative thyroid remnant. Fifty-three patients received a low dose (L) (800 MBq) and 55 patients received a high dose (H) (3700 MBq) of I-131. After total thyroidectomy, thyroid bed I-131 uptake (RAIU) and neck ultrasonography (USG) were performed to determine the remnant volume and the iodine avidity, which were used to calculate the dose delivered to the remnant tissue. The success rate of I-131 ablation was assessed with four different criteria based on serum thyroglobulin (Tg) and USG with and without the utilization of I-131 diagnostic whole-body scintigraphy (DxWBS). Ablation was considered to be successful if patients fulfilled all of the following criteria. (a) Strict criteria based on three tests(i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or up to 0.2% RAIU, and (iii) Tg<0.2 ng/ml; (b) lax criteria based on three tests(i) USG negative, (ii) no tracer uptake or less than twice the background activity in the thyroid bed on DxWBS and/or ≤0.2% RAIU, and (iii) Tg<2 ng/ml; (c) strict criteria based on two tests(i) USG negative and (ii) Tg <0.2 ng/ml; (d) lax criteria based on two test(i) USG negative and (ii) Tg <2 ng/ml. RESULTSWhen three tests were used to define successful ablation, in group L, 32 out of 53 (60%) and 43 out of 53 (81%) patients were successfully treated versus 35 out of 55 (64%) and 42 out of 55 (76%) for group H on the basis of strict and lax criteria, respectively (P=NS). The differences were not statistically significant between the two groups when only two tests were used to define ablation success (62 vs. 69% with strict and 89 vs. 87% with lax criteria, respectively). CONCLUSIONOur findings suggest that remnant thyroid tissue in patients with low-risk, well-differentiated thyroid cancer after total thyroidectomy can be ablated with 800 MBq of I-131. The success rate is not different from that obtained with 3700 MBq I-131.
Author Bayraktar, Miyase
Bozkurt, Fani M
Caglar, Meltem
Akca, Ceren Kapulu
Ugur, Omer
Karaağaoğlu, Ergun
Vargol, Sezen Elhan
AuthorAffiliation Departments of aNuclear Medicine bEndocrinology cBiostatistics, Hacettepe University Medical Faculty, Sihhiye Ankara, Turkey
AuthorAffiliation_xml – name: Departments of aNuclear Medicine bEndocrinology cBiostatistics, Hacettepe University Medical Faculty, Sihhiye Ankara, Turkey
Author_xml – sequence: 1
  givenname: Meltem
  surname: Caglar
  fullname: Caglar, Meltem
  organization: Departments of aNuclear Medicine bEndocrinology cBiostatistics, Hacettepe University Medical Faculty, Sihhiye Ankara, Turkey
– sequence: 2
  givenname: Fani
  surname: Bozkurt
  middlename: M
  fullname: Bozkurt, Fani M
– sequence: 3
  givenname: Ceren
  surname: Akca
  middlename: Kapulu
  fullname: Akca, Ceren Kapulu
– sequence: 4
  givenname: Sezen
  surname: Vargol
  middlename: Elhan
  fullname: Vargol, Sezen Elhan
– sequence: 5
  givenname: Miyase
  surname: Bayraktar
  fullname: Bayraktar, Miyase
– sequence: 6
  givenname: Omer
  surname: Ugur
  fullname: Ugur, Omer
– sequence: 7
  givenname: Ergun
  surname: Karaağaoğlu
  fullname: Karaağaoğlu, Ergun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22205241$$D View this record in MEDLINE/PubMed
BookMark eNp9Uctu1DAUtVARnRb-ACHvWKVcP-IkSxhRWqkDG1hHjn2jmCZ2ansY9Tv6wzWa0gWLru6R7nlI55yREx88EvKewQWDrvm0-767gAGYQMFbIdHUVr0iGyYbUdWKtydkA0yKSiihTslZSr8BoBWqeUNOOedQc8k25GEbllVHl4KnYaQtANXeUtEUsPtyR12wzmPFBKNjiDRPSNeQclgx6uz-INXDXMBRnaf7GJylERevfabO07U80edEDy5PdA6HqmTdUuvGEWN5OJ3RPguN9gbjW_J61HPCd0_3nPy6_Ppze1Xd_Ph2vf18UxlR16rqakBrRMOswVKIRT1whS0HbflolJbIQHVccdMw1jHDBimbth4VsFpZBeKcfDz6rjHc7THlfnHJ4Dxrj2Gf-o41rJYAvDDlkWliSCni2K_RLTre9wz6v2v0ZY3-_zWK7MNTwH5Y0D6L_tVfCO2RcAhzxphu5_0BYz-hnvP0svcjcEybTw
CitedBy_id crossref_primary_10_1177_0300060520966491
crossref_primary_10_1016_j_mednuc_2017_03_001
crossref_primary_10_1089_thy_2013_0362
crossref_primary_10_1007_s10354_019_00713_5
crossref_primary_10_1097_MNM_0000000000000727
crossref_primary_10_1053_j_semnuclmed_2023_01_006
crossref_primary_10_1097_RLU_0000000000000914
crossref_primary_10_1530_EJE_12_0954
crossref_primary_10_1210_jc_2012_3682
crossref_primary_10_1089_thy_2015_0658
crossref_primary_10_1089_thy_2017_0136
crossref_primary_10_3413_Nukmed_0733_15_03
crossref_primary_10_12659_MSM_896535
crossref_primary_10_1097_MNM_0000000000000296
crossref_primary_10_1016_j_ejso_2020_01_010
crossref_primary_10_1007_s11604_017_0660_9
crossref_primary_10_3413_Nukmed_0792_16_01
crossref_primary_10_1007_s00268_014_2498_y
crossref_primary_10_3803_EnM_2020_741
crossref_primary_10_1097_MED_0b013e328358c698
crossref_primary_10_1007_s00259_017_3654_z
crossref_primary_10_1097_MD_0000000000035339
crossref_primary_10_2967_jnumed_117_191338
crossref_primary_10_1080_0284186X_2020_1785003
crossref_primary_10_1097_MD_0000000000007164
crossref_primary_10_1097_MNM_0000000000000636
crossref_primary_10_1097_MNM_0000000000000730
crossref_primary_10_1007_s12020_014_0333_8
crossref_primary_10_1097_RLU_0000000000001190
crossref_primary_10_1007_s00270_016_1313_6
crossref_primary_10_7759_cureus_12937
crossref_primary_10_7314_APJCP_2013_14_5_3213
Cites_doi 10.1056/NEJM198310203091601
10.1089/thy.1997.7.183
10.1210/jc.2003-031152
10.1210/jcem.87.4.8274
10.1210/jc.2002-021925
10.1007/s00259-009-1315-6
10.1016/j.clon.2008.03.010
10.1056/NEJM199801293380506
10.1089/thy.2006.16.37
10.1016/S0167-8140(98)00012-7
10.1259/0007-1285-65-778-905
10.1016/S0889-8529(18)30319-0
10.7326/0003-4819-96-1-51
10.1530/eje.0.1480019
10.1210/jcem-71-2-414
10.1016/j.ijrobp.2004.01.036
10.1530/eje.0.1510539
10.1259/bjr.71.843.9616241
10.1210/jcem.86.4.7407
10.1046/j.1365-2265.2000.01014.x
10.1016/0002-9343(94)90321-2
ContentType Journal Article
Copyright 2012 Lippincott Williams & Wilkins, Inc.
Copyright_xml – notice: 2012 Lippincott Williams & Wilkins, Inc.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1097/MNM.0b013e32834ec5d6
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1473-5628
EndPage 274
ExternalDocumentID 10_1097_MNM_0b013e32834ec5d6
22205241
10.1097/MNM.0b013e32834ec5d6
Genre Randomized Controlled Trial
Journal Article
Comparative Study
GroupedDBID -
.Z2
0R
123
4Q1
4Q2
4Q3
53G
5VS
71W
8L-
8WZ
A6W
AAPBV
AARTV
AAYEP
ABBUW
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFS
ACWDW
ACWRI
ACXNZ
ADFPA
ADNKB
AE3
AENEX
AFUWQ
AHULI
AHVBC
AJIOK
AJNYG
ALMA_UNASSIGNED_HOLDINGS
AMJPA
ASCII
AWKKM
BQLVK
C45
CAG
COF
CS3
DU5
DUNZO
E.X
EBS
EJD
EX3
F2K
F2L
F5P
FL-
H0
H0~
HZ
IN
IN~
JF9
JG8
JK3
JK8
K8S
KD2
KMI
L-C
N9A
N~M
O9-
OAG
OAH
OCUKA
ODA
OHASI
OL1
OLG
OLV
OLW
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OWW
OWY
OXXIT
P-K
P2P
R58
RIG
RLZ
RSW
S4R
S4S
V2I
WOQ
WOW
X3V
X3W
Z2
ZA5
ZGI
---
.-D
0R~
AAAAV
AAHPQ
AAIQE
AASCR
ABASU
ABDIG
ABJNI
ABVCZ
ACGFO
ACILI
ACXJB
ADGGA
ADHPY
AE6
AEETU
AFDTB
AGINI
AHQNM
AHRYX
AINUH
AJNWD
AJZMW
ALMTX
AMKUR
AMNEI
AOHHW
BS7
CGR
CUY
CVF
DIWNM
ECM
EEVPB
EIF
FCALG
GNXGY
GQDEL
HLJTE
HZ~
IKREB
IPNFZ
NPM
OWU
OWV
OWX
OWZ
T8P
TEORI
TSPGW
VVN
W3M
XXN
XYM
ZFV
ZZMQN
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c3556-950edc371dce097deab26e820ad2fc6a4e1069262c71191c1b44785f60156d603
ISSN 0143-3636
IngestDate Fri Aug 16 02:12:20 EDT 2024
Fri Aug 23 02:11:37 EDT 2024
Sat Sep 28 07:59:22 EDT 2024
Thu Aug 13 19:53:35 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3556-950edc371dce097deab26e820ad2fc6a4e1069262c71191c1b44785f60156d603
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
PMID 22205241
PQID 917154002
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_917154002
crossref_primary_10_1097_MNM_0b013e32834ec5d6
pubmed_primary_22205241
wolterskluwer_health_10_1097_MNM_0b013e32834ec5d6
ProviderPackageCode L-C
C45
AARTV
ADFPA
ASCII
OLG
ODA
ABZAD
ABBUW
JK3
ADNKB
JK8
H0~
OLV
8L-
JG8
OLW
OLZ
F2K
F2L
OHASI
AHVBC
AJNYG
FL-
KMI
K8S
AJIOK
OPUJH
V2I
S4R
S4S
4Q1
DUNZO
OAG
4Q2
OVDNE
4Q3
AMJPA
OAH
OVD
71W
AHULI
ACEWG
.Z2
AWKKM
OUVQU
ORVUJ
X3V
X3W
ACDDN
ACWRI
E.X
OWW
OCUKA
OWY
ACXNZ
OL1
ABXVJ
IN~
KD2
OXXIT
ACWDW
JF9
PublicationCentury 2000
PublicationDate 2012-March
2012-Mar
2012-03-00
20120301
PublicationDateYYYYMMDD 2012-03-01
PublicationDate_xml – month: 03
  year: 2012
  text: 2012-March
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Nuclear medicine communications
PublicationTitleAlternate Nucl Med Commun
PublicationYear 2012
Publisher Lippincott Williams & Wilkins, Inc
Publisher_xml – name: Lippincott Williams & Wilkins, Inc
References Mazzaferri (R2-8-20210212) 1994; 97
Doi (R16-8-20210212) 2000; 52
Torlontano (R26-8-20210212) 2003; 148
Robbins (R27-8-20210212) 2005; 46
DeGroot (R1-8-20210212) 1990; 71
Johansen (R7-8-20210212) 1991; 32
Mallick (R36-8-20210212) 2008; 20
Schlumberger (R3-8-20210212) 1998; 338
Maxon (R32-8-20210212) 1997; 7
Pacini (R13-8-20210212) 2006; 154
Samuel (R30-8-20210212) 1994; 3335
Bierwaltes (R14-8-20210212) 1984; 25
DeGroot (R19-8-20210212) 1982; 96
Maxon (R31-8-20210212) 1983; 309
Jeevanram (R34-8-20210212) 1986; 13
Zidan (R21-8-20210212) 2004; 59
Bal (R8-8-20210212) 2004; 89
Pacini (R24-8-20210212) 2003; 88
Doi (R5-8-20210212) 2000; 52
Hodgson (R20-8-20210212) 1998; 47
Synder (R12-8-20210212) 1983; 24
Schlumberger (R28-8-20210212) 2004; 151
Mazzaferri (R15-8-20210212) 2001; 96
Maxon (R29-8-20210212) 1992; 33
Wong (R4-8-20210212) 1990; 19
Leung (R17-8-20210212) 1992; 65
Pacini (R23-8-20210212) 2002; 87
Hadjieva (R33-8-20210212) 1985; 26
Miccoli (R10-8-20210212) 2006; 16
Lin (R22-8-20210212) 1998; 71
Verburg (R35-8-20210212) 2010; 37
References_xml – volume: 309
  start-page: 937
  year: 1983
  ident: R31-8-20210212
  article-title: Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer.
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198310203091601
  contributor:
    fullname: Maxon
– volume: 32
  start-page: 252
  year: 1991
  ident: R7-8-20210212
  article-title: Comparison of 1073 MBq and 3700 MBq iodine-131 in the postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer.
  publication-title: J Nucl Med
  contributor:
    fullname: Johansen
– volume: 46
  start-page: 28S
  year: 2005
  ident: R27-8-20210212
  article-title: The evolving role of I-131 for the treatment of differentiated thyroid carcinoma.
  publication-title: J Nucl Med
  contributor:
    fullname: Robbins
– volume: 7
  start-page: 183
  year: 1997
  ident: R32-8-20210212
  article-title: Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer.
  publication-title: Thyroid
  doi: 10.1089/thy.1997.7.183
  contributor:
    fullname: Maxon
– volume: 89
  start-page: 1666
  year: 2004
  ident: R8-8-20210212
  article-title: Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 506 patients.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2003-031152
  contributor:
    fullname: Bal
– volume: 87
  start-page: 1499
  year: 2002
  ident: R23-8-20210212
  article-title: Diagnostic I-131 iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem.87.4.8274
  contributor:
    fullname: Pacini
– volume: 88
  start-page: 3668
  year: 2003
  ident: R24-8-20210212
  article-title: Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2002-021925
  contributor:
    fullname: Pacini
– volume: 37
  start-page: 276
  year: 2010
  ident: R35-8-20210212
  article-title: No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-009-1315-6
  contributor:
    fullname: Verburg
– volume: 20
  start-page: 325
  year: 2008
  ident: R36-8-20210212
  article-title: The Hilo trial: a multicentre randomised trial of high versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer.
  publication-title: Clin Oncol
  doi: 10.1016/j.clon.2008.03.010
  contributor:
    fullname: Mallick
– volume: 338
  start-page: 297
  year: 1998
  ident: R3-8-20210212
  article-title: Papillary and follicular thyroid carcinoma.
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199801293380506
  contributor:
    fullname: Schlumberger
– volume: 16
  start-page: 37
  year: 2006
  ident: R10-8-20210212
  article-title: Ultrasonography estimated thyroid volume: a prospective study about its reliability.
  publication-title: Thyroid
  doi: 10.1089/thy.2006.16.37
  contributor:
    fullname: Miccoli
– volume: 47
  start-page: 325
  year: 1998
  ident: R20-8-20210212
  article-title: Prescribing I-131 iodine based on neck uptake produces effective thyroid ablation and reduced hospiatl stay.
  publication-title: Radiother Oncol
  doi: 10.1016/S0167-8140(98)00012-7
  contributor:
    fullname: Hodgson
– volume: 13
  start-page: 277
  year: 1986
  ident: R34-8-20210212
  article-title: Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients.
  publication-title: Nucl Med Biol
  contributor:
    fullname: Jeevanram
– volume: 65
  start-page: 905
  year: 1992
  ident: R17-8-20210212
  article-title: Efficacy of low-dose iodine-131 ablation of postoperative thyroid remnants: a study of 69 cases.
  publication-title: Br J Radiol
  doi: 10.1259/0007-1285-65-778-905
  contributor:
    fullname: Leung
– volume: 19
  start-page: 741
  year: 1990
  ident: R4-8-20210212
  article-title: Ablative radioactive iodine therapy for apparently localized thyroid carcinoma: a decision analytic perspective.
  publication-title: Endocrinol Metab Clin North Am
  doi: 10.1016/S0889-8529(18)30319-0
  contributor:
    fullname: Wong
– volume: 96
  start-page: 51
  year: 1982
  ident: R19-8-20210212
  article-title: Comparison of 30 and 50 mCi doses of iodine-131 for thyroid ablation.
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-96-1-51
  contributor:
    fullname: DeGroot
– volume: 148
  start-page: 19
  year: 2003
  ident: R26-8-20210212
  article-title: Serum thyroglobulin and I-131 whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
  publication-title: Eur J Endocrinol
  doi: 10.1530/eje.0.1480019
  contributor:
    fullname: Torlontano
– volume: 71
  start-page: 414
  year: 1990
  ident: R1-8-20210212
  article-title: Natural history, treatment and course of papillary thyroid carcinoma.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem-71-2-414
  contributor:
    fullname: DeGroot
– volume: 59
  start-page: 1330
  year: 2004
  ident: R21-8-20210212
  article-title: Efficacy of I-131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer.
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2004.01.036
  contributor:
    fullname: Zidan
– volume: 151
  start-page: 539
  year: 2004
  ident: R28-8-20210212
  article-title: Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice.
  publication-title: Eur J Endocrinol
  doi: 10.1530/eje.0.1510539
  contributor:
    fullname: Schlumberger
– volume: 71
  start-page: 307
  year: 1998
  ident: R22-8-20210212
  article-title: The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma.
  publication-title: Br J Radiol
  doi: 10.1259/bjr.71.843.9616241
  contributor:
    fullname: Lin
– volume: 33
  start-page: 1132
  year: 1992
  ident: R29-8-20210212
  article-title: Radioiodine I-131 therapy for well differentiated thyroid cancer - a quantitative radiation - dosimetric approach: outcome and validation in 85 patients.
  publication-title: J Nucl Med
  contributor:
    fullname: Maxon
– volume: 96
  start-page: 1447
  year: 2001
  ident: R15-8-20210212
  article-title: Current approaches to primary therapy for papillary and follicular thyroid cancer.
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem.86.4.7407
  contributor:
    fullname: Mazzaferri
– volume: 25
  start-page: 1284
  year: 1984
  ident: R14-8-20210212
  article-title: An analysis of ablation of thyroid remnants with I-131 in 511 patients from 1947-1984: experiences at University of Michigan.
  publication-title: J Nucl Med
  contributor:
    fullname: Bierwaltes
– volume: 52
  start-page: 763
  year: 2000
  ident: R5-8-20210212
  article-title: Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer.
  publication-title: Clin Endocrinol
  doi: 10.1046/j.1365-2265.2000.01014.x
  contributor:
    fullname: Doi
– volume: 154
  start-page: 787
  year: 2006
  ident: R13-8-20210212
  article-title: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
  publication-title: Eur J Nucl Med
  contributor:
    fullname: Pacini
– volume: 52
  start-page: 765
  year: 2000
  ident: R16-8-20210212
  article-title: Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
  publication-title: Clin Endocrinol
  doi: 10.1046/j.1365-2265.2000.01014.x
  contributor:
    fullname: Doi
– volume: 3335
  start-page: 1944
  year: 1994
  ident: R30-8-20210212
  article-title: Radioiodine therapy for well differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid after surgery.
  publication-title: J Nucl Med
  contributor:
    fullname: Samuel
– volume: 97
  start-page: 418
  year: 1994
  ident: R2-8-20210212
  article-title: Long term impact of initial surgical and medical therapy on papillary anf follicular thyroid cancer.
  publication-title: Am J Med
  doi: 10.1016/0002-9343(94)90321-2
  contributor:
    fullname: Mazzaferri
– volume: 24
  start-page: 659
  year: 1983
  ident: R12-8-20210212
  article-title: Thyroid remnant ablation: questionable pursuit of an ill defined goal.
  publication-title: J Nucl Med
  contributor:
    fullname: Synder
– volume: 26
  start-page: 819
  year: 1985
  ident: R33-8-20210212
  article-title: Quantitative approach to radioiodine ablation of thyroid remnants following surgery for thyroid cancer.
  publication-title: Radiobiol Radiother
  contributor:
    fullname: Hadjieva
SSID ssj0008367
Score 2.200701
Snippet INTRODUCTIONThe initial treatment of differentiated thyroid cancer is thyroidectomy, followed by remnant ablation with iodine-131 (I-131) in some patients....
The initial treatment of differentiated thyroid cancer is thyroidectomy, followed by remnant ablation with iodine-131 (I-131) in some patients. However,...
SourceID proquest
crossref
pubmed
wolterskluwer
SourceType Aggregation Database
Index Database
Publisher
StartPage 268
SubjectTerms Adenocarcinoma, Follicular - radiotherapy
Adenocarcinoma, Follicular - surgery
Adult
Aged
Carcinoma, Papillary - radiotherapy
Carcinoma, Papillary - surgery
Female
Follow-Up Studies
Humans
Iodine Radioisotopes - administration & dosage
Male
Middle Aged
Neck - diagnostic imaging
Prospective Studies
Thyroglobulin - blood
Thyroid Gland - radiation effects
Thyroid Neoplasms - radiotherapy
Thyroid Neoplasms - surgery
Thyroidectomy
Treatment Outcome
Ultrasonography
Whole Body Imaging - methods
Young Adult
Title Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/22205241
https://search.proquest.com/docview/917154002
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwGLW6TUIghLhTbvIDb5WhcZzbYymtNtGWh3Vob5FjO6NqSUpLNGl_gz_M59hOWjZxeeAlihLZiXJOPh_b3wWhN5TmygMZSoTIKGEwISBZGCniC-HTnEmP53rB7fg0mp3HH0Zs1Om46njttf-KNFwDrHXk7D-g3XQKF-AcMIcjoA7Hv8J9uFtYsAdCrd4e8CM4mb7_1luUMFgp4vle42C41rk11sqmAOfZqlGRAOKmXOj4lq_aX6bX5mG1QXGr8pLUzumuzgrYCy1hXUOhObXZFcAznT-Zb5o9fe3T3kaoNAJ_yEHW12SaqpVbXq69Gq-WlYkyGvNi0a7lDpailsFD_Ra9j3xdrSp37zPfXJhCYqfqCu6OVl_sP2GXO7TfiPP3equMiWaRT0C1xbs23CTTsFz1dw2yKdpjx3ZqKgJdGzZMOuLpbOrWhUF0MSUCeUOW7tmndHw2maTz0fn8AB1RMHBgX48Gw5PJSaMBYj-MXKBmEr27qed9IXRtdnMH3b0stcPEdlnHS-yonvl9dM9OV_DA8OwB6qjiIbo1teA9Qj9auuEyx0A3DHTDmm4Y6IZbumGgGwa64T26YUc33dqyBlu64UWBHd2wpht2dMP7dGsaGro9Rmfj0Xx4TGydDyJA7YYkCfpKCj_ypFDwtaTiGQ0VSFMuaS5CzpTXD3VeSxHpdITCyxiL4iAPdRoAGfb9J-iwKAv1DGEVy0Bm0IGkCctilgU0kZTGSaCYSkKvi4j76OnapHNJnRsGgJT-ClIXYYdMCnZXb6bxQpXVNgWrBrMP0BNd9NQg1nRIdfA6KOMu8vYgTE1o828f-PzPD3yBbrc_xkt0-H1TqVfoYCur15aGPwEaiL9u
link.rule.ids 315,782,786,27933,27934
linkProvider Ovid
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+800+and+3700+MBq+iodine-131+for+the+postoperative+ablation+of+thyroid+remnant+in+patients+with+low-risk+differentiated+thyroid+cancer&rft.jtitle=Nuclear+medicine+communications&rft.au=Caglar%2C+Meltem&rft.au=Bozkurt%2C+Fani+M&rft.au=Akca%2C+Ceren+Kapulu&rft.au=Vargol%2C+Sezen+Elhan&rft.date=2012-03-01&rft.eissn=1473-5628&rft.volume=33&rft.issue=3&rft.spage=268&rft.epage=274&rft_id=info:doi/10.1097%2FMNM.0b013e32834ec5d6&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0143-3636&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0143-3636&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0143-3636&client=summon